Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02383927 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
A Phase 2 study, sponsored by Kura Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT02383927 is a Phase 2 study that has completed, run by Kura Oncology. The registered enrollment target is 63 participants.
The verdict
NCT02383927, a Phase 2 study, has completed, sponsored by Kura Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available.
Interventions
- DRUG Tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2015-05-13 |
| Est. Completion | 2020-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02383927
The ClinicalTrials.gov registry entry for NCT02383927 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kura Oncology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tipifarnib is the first listed.
NCT02383927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02383927 about?
NCT02383927 is a clinical study titled "Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations". Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available.
What is the current status of trial NCT02383927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2015-05-13. Estimated completion is 2020-12-14.
What interventions are being tested in trial NCT02383927?
The interventions under investigation include: Tipifarnib (DRUG).
Who is sponsoring clinical trial NCT02383927?
This trial is sponsored by Kura Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.